WORLD PEPTIDEFOUNDATION

Where is Pemvidutide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Pemvidutide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

GLP-1/glucagon receptor agonist

Pemvidutide

Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.

Record status

Traceability partial

Last meaningful update: 9/26/2026

Evidence searched through:
Not recorded
Assessment updated:
9/26/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

32

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

5

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

24

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

32

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

5

Independent evidence dossiers covering the major research questions.

Published source records

24

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

5 published domain syntheses connected to 0 featured studies

Pemvidutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record24 governed records · titles, provenance, and original-source linksOpen records ↓
2025Phase 1–2 human evidence

Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

Content-verified record concerning Pemvidutide: "Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial." Abstract excerpt: This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Completers of a double-blind trial of pemvidutide in MASLD, who were previously randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or

Source
peer_reviewed_research
DOI
10.1016/j.jhepr.2025.101483
PubMed
41113119
Open original source
2025Animal research

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.

Randomized study in MASLD; endpoint and follow-up require full-text appraisal.

Source
peer_reviewed_research
DOI
10.1016/j.jhep.2024.07.006
PubMed
39002641
Open original source
2025Animal research

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

Content-verified record concerning Pemvidutide: "Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study." Abstract excerpt: GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment. IMPACT is an ongoing 48-week international, randomised, double-blind,

Source
peer_reviewed_research
DOI
10.1016/S0140-6736(25)02114-2
PubMed
41237796
Open original source
Insufficient evidence

TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(26)01885-4
Open original source
Insufficient evidence

228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db24-228-or
Open original source
Insufficient evidence

FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(26)01936-7
Open original source
Insufficient evidence

OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(26)00326-0
Open original source
Insufficient evidence

748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db25-748-p
Open original source
Insufficient evidence

228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db25-228-or
Open original source
Insufficient evidence

778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db25-778-p
Open original source
Insufficient evidence

SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(25)01709-x
Open original source
2025Insufficient evidence

The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.

Content-verified record concerning Pemvidutide: "The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1016/s0140-6736(25)02304-9
PubMed
41352959
Open original source
Insufficient evidence

Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.64898/2025.12.22.25342824
Open original source
Insufficient evidence

WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(24)01560-5
Open original source
Insufficient evidence

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db24-262-or
Open original source
Insufficient evidence

WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(24)01555-1
Open original source
Insufficient evidence

WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(24)01588-5
Open original source
Insufficient evidence

Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(23)00517-2
Open original source
Insufficient evidence

334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db22-334-or
Open original source
Insufficient evidence

Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1161/circ.146.suppl_1.13440
Open original source
Insufficient evidence

Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(22)00570-0
Open original source
Insufficient evidence

749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/db25-749-p
Open original source
2026Insufficient evidence

Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.

Content-verified record concerning Pemvidutide: "Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials." Abstract excerpt: Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to es

Source
systematic_review_or_meta_analysis
DOI
10.1007/s00210-026-05257-1
PubMed
41879841
Open original source
Insufficient evidence

LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial

Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0168-8278(26)00451-4
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Amino acid sequence
His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Ala-Ala-Lys-Glu-Phe-Ile-Gln-Trp-Leu-Leu-Gln-Thr-NH2

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 2025 · study · Temporal status not established

    Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

    peer_reviewed_research

  2. 2025 · study · Temporal status not established

    Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.

    peer_reviewed_research

  3. 2025 · study · Temporal status not established

    Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

    peer_reviewed_research

  4. 2025 · study · Temporal status not established

    The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.

    peer_reviewed_research

  5. 2026 · study · Temporal status not established

    Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.

    systematic_review_or_meta_analysis

  6. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    European Union — EMA

  7. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States — FDA

  8. Date unavailable · study · Temporal status not established

    TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis

    other

  9. Date unavailable · study · Temporal status not established

    228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids

    other

  10. Date unavailable · study · Temporal status not established

    FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial

    other

  11. Date unavailable · study · Temporal status not established

    OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis

    other

  12. Date unavailable · study · Temporal status not established

    748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide

    other

  13. Date unavailable · study · Temporal status not established

    228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

    other

  14. Date unavailable · study · Temporal status not established

    778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model

    other

  15. Date unavailable · study · Temporal status not established

    SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)

    other

  16. Date unavailable · study · Temporal status not established

    Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials

    other

  17. Date unavailable · study · Temporal status not established

    WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model

    other

  18. Date unavailable · study · Temporal status not established

    262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

    other

  19. Date unavailable · study · Temporal status not established

    WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial

    other

  20. Date unavailable · study · Temporal status not established

    WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis

    other

  21. Date unavailable · study · Temporal status not established

    Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial

    other

  22. Date unavailable · study · Temporal status not established

    334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity

    other

  23. Date unavailable · study · Temporal status not established

    Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators

    other

  24. Date unavailable · study · Temporal status not established

    Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial

    other

  25. Date unavailable · study · Temporal status not established

    749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

    other

  26. Date unavailable · study · Temporal status not established

    LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 3 represented connections ↓

institution

other

represented evidence source

institution

peer_reviewed_research

represented evidence source

institution

systematic_review_or_meta_analysis

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 5 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Pemvidutide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

United States — FDA

Regulator: FDA

not_approved

As of: 9/23/2026 · Temporal status not established

FDA Drugs@FDA database

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:49 PM

global evidence atlas

Pemvidutide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

32Discoverable source universe
32Ranked screening records
5Research domains
0Accountably approved conclusions

32 matching records · ranked 2026-09-18

Page 1 of 2

Count reconciliation: 32 discoverable source records match the peptide identity query; 32 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

Pemvidutide: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Known limitations of this pass

  • no current regulatory record located in governed sources

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Pemvidutide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Pemvidutide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 26, 2026.) https://www.worldpeptidefoundation.org/directory/pemvidutide

  • AMA / Vancouver

    World Peptide Foundation. Pemvidutide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 26, 2026. https://www.worldpeptidefoundation.org/directory/pemvidutide